Holen Sie sich die Stockscreener-App
11.00
0.18%
-0.02
Handel nachbörslich:
11.00
Schlusskurs vom Vortag:
$11.02
Offen:
$10.95
24-Stunden-Volumen:
9,704
Relative Volume:
0.33
Marktkapitalisierung:
$99.51M
Einnahmen:
$29.93M
Nettoeinkommen (Verlust:
$-545.30K
KGV:
-182.72
EPS:
-0.0602
Netto-Cashflow:
$3.38M
1W Leistung:
-1.87%
1M Leistung:
+6.38%
6M Leistung:
+76.28%
1J Leistung:
+79.15%
1-Tages-Spanne:
$10.76
$11.03
1-Wochen-Bereich:
$10.50
$11.38
52-Wochen-Spanne:
$4.52
$12.10
Immucell Corp Stock (ICCC) Company Profile
Firmenname
Immucell Corp
Sektor
Branche
Telefon
(207) 878-2770
Adresse
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
11.00 | 100.69M | 29.93M | -545.30K | 3.38M | -0.0602 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immucell Corp Aktie (ICCC) Neueste Nachrichten
ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ICCC|ImmuCell Corp|Price:11.135|Chg%:+0.105 - TradingKey
ImmuCell Corp (ICCC) Cash Flow - TradingKey
ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ImmuCell Corp (ICCC) Institutional Confidence - TradingKey
ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MSN Money - MSN
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand - Yahoo Finance
ImmuCell Corporation Files Form 8-K: Key Financial Data and Company Information for July 2026 - Minichart
ImmuCell reports 11.5% sales increase in second quarter - Investing.com
ImmuCell (ICCC) Reports Significant Growth in Quarterly Sales - GuruFocus
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results - The Manila Times
ImmuCell reports Q2 product sales up 11.5% to $7.2M; six‑month sales up 20.9% to $17.5M - TradingView
ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9% - Stock Titan
ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products - Stock Titan
ImmuCell adds Jacee Lancaster to Commercial Team - Feedstuffs
ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70Inverse ETF Flow - dars.gov.et
ICCC's valuation remains premium: Is it worth overpaying for? - MSN
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell - Yahoo Finance
ImmuCell CEO buys $75,960 in common stock - Investing.com UK
Insider Buying: te Boekhorst Paul Francis Olivier Acquires Additional Shares of ImmuCell Corp (ICCC) - GuruFocus
Form 4 ImmuCell Corporation For: 22 June By Investing.com - Investing.com Nigeria
ImmuCell CEO buys $75,960 in common stock By Investing.com - Investing.com Canada
ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy - Stock Titan
ICCC's Valuation Remains Premium: Is it Worth Overpaying for? - The Globe and Mail
ImmuCell shareholders approve director elections and key proposals at annual meeting - Investing.com
ImmuCell (NASDAQ: ICCC) investors approve directors, pay plan, auditor - Stock Titan
ImmuCell Corp (ICCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ImmuCell Corp (ICCC) Valuation: PE, PB & Fair Value Analysis - TradingKey
ImmuCell (NASDAQ: ICCC) approves $3.5M First Defense expansion plan - Stock Titan
Jonathan Ocampo joins ImmuCell Commercial Team - Feedstuffs
ICCC Q1 2026 Earnings: EPS of $0.21 Reported Without Revenue Disclosure; Stock Declines 3% - DonanımHaber
ICCC Technical Analysis | Trend, Signals & Chart Patterns | IMMUCELL CORP (NASDAQ:ICCC) - ChartMill
ImmuCell Corp. Hits New 52-Week High of $10.65, Up 145% - MarketsMojo
ImmuCell Corporation (ICCC) Surges 3.75% to $10.50 as Bulls Test Key ResistanceNews Sentiment - The Legal Advocate
ImmuCell Shares Rose Ahead of Holiday; Tuesday’s Open in Focus - Bez Kabli
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand - Yahoo Finance
ICCC SEC FilingsImmucell 10-K, 10-Q, 8-K Forms - Stock Titan
ImmuCell Corporation (ICCC) Climbs +10.76% — Resistance at $10.37 in Focus 2026-05-18Median Line - newsline.com
ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript - Insider Monkey
Finanzdaten der Immucell Corp-Aktie (ICCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immucell Corp-Aktie (ICCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BRIGHAM MICHAEL F | Director |
Mar 20 '26 |
Option Exercise |
5.84 |
25,000 |
146,000 |
229,752 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 03 '25 |
Buy |
5.02 |
6,077 |
30,536 |
9,785 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 02 '25 |
Buy |
4.87 |
3,708 |
18,053 |
3,708 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,781 |
4,740 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,773 |
52,720 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):